Dr. Kasner's research interests encompass the development and clinical application of novel therapeutic agents for AML and MDS. She has been involved in Phase I clinical trials investigating sirolimus combined with standard induction chemotherapy in newly diagnosed AML patients . Additionally, her work includes integrating electronic geriatric assessments and frailty screening to personalize treatment decisions for older adults with AML She specializes in hematologic malignancies, with a particular focus on acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and stem cell transplantation.
Margaret T. Kasner, MD
Professor
Contact Information
Honickman Center
1101 Chestnut Street
14th Floor
Philadelphia, PA 19107
Professor
RESEARCH & CLINICAL INTEREST
Education
Medical School
University of Pennsylvania School of Medicine - 2001
Residency
Hospital of University of Pennsylvania (HUP)
Fellowship
Hospital of University of Pennsylvania (HUP)
Most Recent Peer-Reviewed Publications
- Targeting CD47: many misses; hopeful for a hit
- North American Cancer Center Clinical Research Capacity and Benchmarking in the Postpandemic Era
- A Phase I Trial of Sirolimus with “7&3” Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia
- Integrating electronic geriatric assessment and frailty screening for adults with acute myeloid leukemia to drive personalized treatment decisions
- A phase I study of the combination of palbociclib and dexamethasone for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia
Board Certifications
Medical Oncology
Internal Medicine
Hematology